Archives

  • 2026-11
  • 2026-10
  • 2026-09
  • 2026-08
  • 2026-07
  • 2026-06
  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10
  • Carbapenemase Gene Transmission in CREC in Guangdong

    2026-10-07

    Carbapenemase Gene Transmission in CREC in Guangdong

    Carbapenem-resistant Enterobacter cloacae (CREC) is an important component of the wider carbapenem-resistant Enterobacteriaceae problem. The reference study by Chen et al., published in BMC Microbiology in 2025, examines how carbapenemase-encoding genes are distributed, associated with antimicrobial resistance, and potentially mobilized among CREC isolates collected in Guangdong, China. The study is especially relevant to researchers studying plasmid-mediated resistance, hospital surveillance, and the bacterial DNA replication pathway as it relates to fluoroquinolone susceptibility. The full open-access report is available from Chen et al., BMC Microbiology 2025.

    Study Background and Research Question

    The authors frame their work against the increasing clinical importance of CRE and the possibility that healthcare disruption, changing antibiotic exposure, and complex infections may influence resistance patterns. Within China, CREC is reported as a major CRE species, following Klebsiella pneumoniae and Escherichia coli in detection frequency. Carbapenemase-encoding genes are central to this concern because they can reduce susceptibility to carbapenem antibiotics and may be carried on mobile genetic elements.

    The central research question was not simply whether carbapenemase genes were present. Instead, the study asked how frequently these genes occurred in CREC, whether they were located on chromosomes or plasmids, whether they were associated with broader drug resistance, and whether their genetic context was compatible with horizontal dissemination. The authors also examined whether isolates from different hospitals and departments showed evidence of related strain types. Samples were collected from eight teaching hospitals in Guangdong between December 2022 and June 2024, providing a multicenter snapshot rather than a single-institution analysis.

    Key Innovation from the Reference Study

    The principal innovation is the integration of several evidence layers that are often reported separately. Chen et al. combined carbapenemase gene detection with gene-localization analysis, antimicrobial susceptibility results, plasmid-transfer assessment, mobile genetic element profiling, and strain typing. This design helps distinguish several concepts that are frequently conflated: the presence of a resistance gene, its physical location, its potential mobility, and the clonal relatedness of the host isolate.

    This distinction is particularly important for blaNDM-1. A gene detected on a plasmid may have a different dissemination potential from the same gene detected only on a chromosome, although location alone does not establish future transmission. Similarly, related ERIC-PCR profiles can indicate genetic similarity among isolates, but they do not prove a direct transmission event without patient-level epidemiology and temporally resolved sampling. By combining these approaches, the study provides a more informative framework for interpreting CREC surveillance data.

    Conceptual Study Design and Evidence Scope

    The study analyzed 54 CREC isolates from eight teaching hospitals. The authors used a variable-temperature SDS-based plasmid elimination approach and PCR to investigate carbapenemase gene localization. Antimicrobial susceptibility was assessed with broth microdilution, while plasmid conjugation experiments and PCR analysis were used to evaluate whether detected carbapenemase genes could be transferred under the study model. Six categories of mobile genetic elements were profiled, and ERIC-PCR with NTSYS-based analysis was used to classify strain patterns.

    Conceptually, the design moves from detection to interpretation: first identifying carbapenemase genes, then asking where those genes reside, whether their presence corresponds to a broader resistance phenotype, whether transfer can be observed in an experimental system, and whether the bacterial hosts appear genetically related. This layered approach strengthens the mechanistic interpretation compared with a prevalence survey based only on PCR positivity.

    However, the evidence remains bounded by the sample and methods. The isolates were obtained from participating hospitals in one province and do not represent all CREC in China. The transfer experiments measure genetic mobility under laboratory conditions, not the frequency of transmission among patients or across hospital networks. The study is therefore best interpreted as a molecular epidemiology and transferability analysis, rather than a direct reconstruction of hospital transmission chains.

    Core Findings and Why They Matter

    High prevalence of carbapenemase-encoding genes

    Carbapenemase-encoding genes were detected in 46 of 54 isolates, corresponding to 85.19% of the study collection. Among all isolates, 18 strains, or 33.33%, carried blaNDM-1 on both chromosomes and plasmids. A further 25 isolates, or 46.30%, carried blaNDM-1 exclusively on plasmids. Two isolates contained only plasmid-associated blaIMP, and one carried both plasmid-associated blaNDM-1 and blaKPC-2. These findings place blaNDM-1, particularly its plasmid-associated form, at the center of the reported CREC resistance landscape.

    The coexistence of chromosomal and plasmid locations is scientifically meaningful because it suggests that the same resistance determinant may be maintained in more than one genetic compartment. It does not demonstrate that chromosomal copies originated from plasmids or that plasmid carriage will persist in every setting. Nevertheless, the observation supports surveillance strategies that record gene location rather than reporting only a positive or negative molecular result.

    Association with multidrug resistance

    The broth microdilution findings showed that the carbapenemase-positive group had significantly higher resistance rates than the carbapenemase-negative group for imipenem, cefepime, gentamicin, ceftazidime/avibactam, ciprofloxacin, and levofloxacin, with reported statistical significance at P<0.05. The study therefore connects carbapenemase gene carriage with a broader multidrug-resistant phenotype, although the comparison does not imply that every resistance phenotype was caused solely by the detected genes.

    Levofloxacin is relevant here as a tested antimicrobial phenotype, not as the central subject of the paper. As a synthetic fluoroquinolone antibiotic and DNA gyrase inhibitor, it acts within processes linked to bacterial DNA replication. The reference study did not investigate the compound’s molecular pharmacology, clinical efficacy, or resistance mechanism in isolation. It reported a difference in levofloxacin resistance between gene-defined groups, which may reflect the accumulation of multiple resistance determinants and linked mobile elements.

    Strong observed transferability of selected genes

    Transfer experiments produced a reported carbapenemase gene transfer success rate of 95.65%, or 44 of 46 gene-positive isolates. For blaNDM-1, the reported success rate was 95.45%, or 42 of 44 tested isolates. Both blaIMP-positive isolates were reported as transferable, whereas the single blaKPC-2 case was not transferred in the study system. These results support the interpretation that many of the detected determinants had substantial mobility under the experimental conditions.

    That result matters for infection-control research because mobile resistance can spread independently of expansion by one bacterial clone. At the same time, transferability is not equivalent to clinical transmission. Successful laboratory transfer does not establish that transfer occurred in a patient, that the recipient strain would remain viable, or that the resulting genotype would persist under clinical antibiotic exposure.

    Mobile elements and strain diversity

    Six types of mobile genetic elements were identified, with ISEcp1 reported in 47 of 54 isolates, or 87.04%. Isolates carrying four mobile-element types simultaneously were the largest category, accounting for 22 of 54 strains, or 40.74%. These observations reinforce the view that resistance surveillance should consider the surrounding genetic architecture, not only the carbapenemase gene name.

    ERIC-PCR and NTSYS analysis divided the 54 isolates into 17 genotypes. Types E and G were each represented by 11 isolates, or 20.37%, and were found across different departments in five hospitals. Two type E isolates shared a Dice coefficient of 100%. This pattern indicates both genetic relatedness and diversity within the sampled population. It is compatible with a mixed dissemination model involving mobile genes, repeated introductions, and possibly clonal expansion, but it cannot distinguish these explanations without more detailed genomic and patient-linked data.

    Comparison with Existing Internal Articles

    The internal article Carbapenemase Gene Transmission in CREC in Guangdong summarizes the same study’s integrated approach and appropriately emphasizes plasmid-associated blaNDM-1 as a surveillance concern. The present interpretation adds an important qualification: the study demonstrates transferability and genetic relatedness patterns, but not confirmed patient-to-patient transmission.

    A separate internal resource, Levofloxacin: Research Context and Evidence, places levofloxacin across antimicrobial-resistance and cell-biology research. That broader context should not be confused with the evidence in Chen et al. The Guangdong paper provides comparatively direct multicenter resistance data, whereas osteoblast or cartilage-related claims come from different sources and should be evaluated independently.

    Limitations and Transferability

    Several limitations define how the findings should be used. First, the sample size was modest, with 54 isolates, and the hospitals were all located in Guangdong. Prevalence estimates may therefore differ in other provinces, healthcare systems, or time periods. Second, the study period from late 2022 through mid-2024 provides a defined surveillance window but cannot establish long-term trends or prove that pandemic-related factors caused the observed patterns.

    Third, the use of PCR and plasmid-elimination analysis provides valuable localization evidence but may not resolve complete genomic structure. Whole-genome sequencing, long-read assembly, and direct comparison of plasmid backbones could better define whether similar genes occupy the same mobile platforms. Fourth, ERIC-PCR is useful for grouping isolates but has lower resolution than contemporary whole-genome approaches for reconstructing transmission relationships.

    Fifth, the reported patient distributions should not be interpreted as independent risk factors. Men represented 35 of 54 cases, elderly patients 39 of 54, respiratory medicine 11 of 54, and sputum samples 18 of 54. These are descriptive frequencies within the sampled collection, not population-adjusted incidence estimates. Finally, the reference study is not an osteoblast growth inhibition assay, calcium deposition inhibition study, or chondrocyte glycosaminoglycan synthesis study. Those biological questions belong to separate research areas and should not be inferred from the CREC findings.

    Research Support Resources

    For researchers reviewing the levofloxacin susceptibility context reported in the paper, Levofloxacin (SKU B1959) is listed as a material relevant to research use. The reference study does not establish formulation, dosing, clinical effectiveness, or cross-domain effects, so its reported resistance comparison should remain the primary evidentiary basis for interpreting the compound in this article’s context.